Clinical Trial Update: Cortical Excitability: Phenotype and Biomarker in Attention-deficit, Hyperactivity Disorder (ADHD) Therapy [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating cortical excitability phenotype and biomarkers in attention-deficit/hyperactivity disorder. Current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Snippet

Sponsor: University of Cincinnati | Conditions: Attention Deficit Disorder With Hyperactivity | Phase 3 | Status: UNKNOWN